These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38526154)

  • 1. Use of Terlipressin in AKI Associated with Hepatorenal Syndrome: COMMENTARY.
    Allegretti AS
    Kidney360; 2024 Jun; 5(6):799-801. PubMed ID: 38526154
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of Terlipressin in AKI Associated with Hepatorenal Syndrome: CON.
    Willows J; Hiremath S
    Kidney360; 2024 Jun; 5(6):795-798. PubMed ID: 38526155
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of Terlipressin in AKI Associated with Hepatorenal Syndrome: PRO.
    Belcher JM
    Kidney360; 2024 Jun; 5(6):791-794. PubMed ID: 38526157
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?
    Roy A; Kajal K; Izzy M; Sihag BK; Premkumar M
    Hepatology; 2024 Jun; 79(6):E163-E164. PubMed ID: 38441911
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter to the Editor: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?
    Guo Q; Wang J; Wang G; Wang X
    Hepatology; 2024 Jun; 79(6):E161-E162. PubMed ID: 38456783
    [No Abstract]   [Full Text] [Related]  

  • 6. Terlipressin for hepatorenal syndrome.
    Wong F
    Curr Opin Gastroenterol; 2024 May; 40(3):156-163. PubMed ID: 38353275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance.
    Allegretti AS; Subramanian RM; Francoz C; Olson JC; Cárdenas A
    Liver Int; 2022 Oct; 42(10):2124-2130. PubMed ID: 35838488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis.
    Wang H; Liu A; Bo W; Feng X; Hu Y
    Medicine (Baltimore); 2018 Apr; 97(16):e0431. PubMed ID: 29668606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Terlipressin. Type I hepatorenal syndrome: an extra window of time before liver transplantation.
    Prescrire Int; 2006 Dec; 15(86):220. PubMed ID: 17171813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome.
    Kim HR; Lee YS; Yim HJ; Lee HJ; Ryu JY; Lee HJ; Yoon EL; Lee SJ; Hyun JJ; Jung SW; Koo JS; Choung RS; Lee SW; Choi JH
    Clin Mol Hepatol; 2013 Dec; 19(4):417-20. PubMed ID: 24459647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
    Neri S; Pulvirenti D; Malaguarnera M; Cosimo BM; Bertino G; Ignaccolo L; Siringo S; Castellino P
    Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terlipressin for hepatorenal syndrome: opportunities and challenges.
    Singal AK; Jalan R
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):104-106. PubMed ID: 36620975
    [No Abstract]   [Full Text] [Related]  

  • 13. Terlipressin-induced vasoconstriction reversed with N-acetylcysteine: a case for combined use in hepatorenal syndrome?
    Sen S; Mookerjee RP; Jalan R
    Gastroenterology; 2002 Dec; 123(6):2160-1. PubMed ID: 12454887
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of treatment with terlipressin plus albumin in hepatorenal syndrome diagnosed with the new acute kidney injury versus the conventional criteria.
    Kalambokis GN; Christaki M; Tsiakas I; Despotis G; Milionis HJ
    Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1292-1294. PubMed ID: 31498285
    [No Abstract]   [Full Text] [Related]  

  • 15. Noradrenaline or terlipressin for hepatorenal syndrome?
    Celis P; Rada G
    Medwave; 2015 Aug; 15 Suppl 2():e6235. PubMed ID: 26334297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terlipressin in hepatorenal syndrome.
    Mazur JE; Cooper TB; Dasta JF
    Ann Pharmacother; 2011 Mar; 45(3):380-7. PubMed ID: 21386023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1.
    Kalambokis GN; Baltayiannis G; Christodoulou D; Christou L
    Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1428-1429. PubMed ID: 29111999
    [No Abstract]   [Full Text] [Related]  

  • 18. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.
    Allegretti AS; Israelsen M; Krag A; Jovani M; Goldin AH; Schulman AR; Winter RW; Gluud LL
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD005162. PubMed ID: 29943803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome.
    Velez JCQ; Wong F; Reddy KR; Sanyal AJ; Vargas HE; Curry MP; Gonzalez SA; Pappas SC; Jamil K
    Kidney360; 2023 Aug; 4(8):1030-1038. PubMed ID: 37143199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Board Review Vignette: Lessons Learned in the Management of Hepatorenal Syndrome Type 1 With Terlipressin.
    Gonzalez SA; Velez JCQ
    Am J Gastroenterol; 2022 Apr; 117(4):520-523. PubMed ID: 35029160
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.